Clinical significance of RKIP and phosphorylated RKIP expression in human cancers

Forum on Immunopathological Diseases and Therapeutics

Volumn 2, Issue 2, 2011, Pages 171-178

  Goodglick, Lee ^a   Bonavida, Benjamin ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Metastasis; Phosphorylated RKIP; pRKIP; Prognosis; RKIP; RKIP pRKIP expression; Therapy resistance

Indexed keywords

I KAPPA B KINASE ALPHA; I KAPPA B KINASE BETA; PHOSPHATIDYLETHANOLAMINE BINDING PROTEIN; PHOSPHOPROTEIN; PROTEIN KINASE C; RAF PROTEIN; TRANSFORMING GROWTH FACTOR BETA ACTIVATED KINASE 1;

ANTIBODY DETECTION; BREAST CANCER; CANCER CELL; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CELL DIFFERENTIATION; CELL PROLIFERATION; COLORECTAL CANCER; CONFERENCE PAPER; GASTROINTESTINAL STROMAL TUMOR; GENE EXPRESSION REGULATION; GENETIC ASSOCIATION; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOSURVEILLANCE; LIVER CELL CARCINOMA; LUNG CANCER; MALIGNANT NEOPLASTIC DISEASE; MERKEL CELL TUMOR; MULTIPLE MYELOMA; OVARY CANCER; PHENOTYPE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; STOMACH CANCER; THYROID CANCER;

EID: 79958263613     PISSN: 21518017     EISSN: 21518025     Source Type: Journal    
DOI: 10.1615/ForumImmunDisTher.v2.i2.80     Document Type: Conference Paper

References (30)

1. Granovsky AE, Rosner MR. Raf kinase inhibitory protein: a signal transduction modula tor and metastasis suppressor. Cell Res. 2008;18:452-7. (Pubitemid 351498852)
2. Zeng L, Imamoto A, Rosner MR. Raf kinase inhibitory protein (RKIP): a physiological regulator and future therapeutic target. Expert Opin Ther Targets. 2008;12:1275-87.
3. Baritaki S, Katsman A, Chatterjee D, Yeung KC, Spandidos DA, Bonavida B. Regulation of tumor cell sensitivity to TRAIL-induced apoptosis by the metastatic suppressor Raf kinase inhibitor protein via Yin Yang 1 inhibition and death receptor 5 up-regulation. J Immunol. 2007;179:5441-53.
4. Odabaei G, Chatterjee D, Jazirehi AR, Goodglick L, Yeung K, Bonavida B. Raf-1 kinase inhibitor protein: structure, function, regulation of cell signaling, and pivotal role in apoptosis. Adv Cancer Res. 2004;91:169-200. (Pubitemid 39140959)
5. Keller ET, Fu Z, Brennan M. The biology of a prostate cancer metastasis suppressor protein: Raf kinase inhibitor protein. J Cell Biochem. 2005;94:273-8. (Pubitemid 41420306)
6. Yeung K, Seitz T, Li S, Janosch P, McFerran B, Kaiser C, Fee F, Katsanakis KD, Rose DW, Mischak H, Sedivy JM, Kolch W. Suppression of Raf-1 kinase activity and MAP kinase signalling by RKIP. Nature. 1999;401:173-7. (Pubitemid 29436321)
7. Yeung K, Janosch P, McFerran B, Rose DW, Mischak H, Sedivy JM, Kolch W. Mechanism of suppression of the Raf/MEK/extracellular signal-regulated kinase pathway by the raf kinase inhibitor protein. Mol Cell Biol. 2000;20:3079-85. (Pubitemid 30215020)
8. Yeung KC, Rose DW, Dhillon AS, Yaros D, Gustafsson M, Chatterjee D, McFerran B, Wyche J, Kolch W, Sedivy JM. Raf kinase inhibitor protein interacts with NFkappaB-inducing kinase and TAK1 and inhibits NF-kappaB activation. Mol Cell Biol. 2001;21:7207-17. (Pubitemid 32953475)
9. Corbit KC, Trakul N, Eves EM, Diaz B, Marshall M, Rosner MR. Activation of Raf-1 signaling by protein kinase C through a mechanism involving Raf kinase inhibitory protein. J Biol Chem. 2003;278:13061-8. (Pubitemid 36800074)
10. Fu Z, Smith PC, Zhang L, Rubin MA, Dunn RL, Yao Z, Keller ET. Effects of raf kinase inhibitor protein expression on suppression of prostate cancer metastasis. J Natl Cancer Inst. 2003;95:878-89. (Pubitemid 36833879)
11. Pantazis P, Han Z, Balan K, Wang Y, Wyche JH. Camptothecin and 9-nitrocamptothecin (9NC) as anti-cancer, anti-HIV and cell-differentiation agents. Development of resistance, enhancement of 9NC-induced activities and combination treatments in cell and animal models. Anticancer Res. 2003;23:3623-38. (Pubitemid 37474305)
12. Chatterjee D, Bai Y, Wang Z, Beach S, Mott S, Roy R, Braastad C, Sun Y, Mukhopadhyay A, Aggarwal BB, Darnowski J, Pantazis P, Wyche J, Fu Z, Kitagwa Y, Keller ET, Sedivy JM, Yeung KC.9 RKIP sensitizes prostate and breast cancer cells to drug-induced apoptosis. J Biol Chem. 2004;279:17515-.
13. O'Neill E, Kolch W. Conferring specificity on the ubiquitous Raf/MEK signalling pathway. Br J Cancer. 2004;90:283-8. (Pubitemid 38250615)
14. Nottage M, Siu LL. Rationale for Ras and raf-kinase as a target for cancer therapeutics. Curr Pharm Des. 2002;8:2231-42. (Pubitemid 35189895)
15. Satyamoorthy K, Herlyn M. p16INK4A and familial melanoma. Methods Mol Biol. 2003;222:185-95.
16. Schuierer MM, Bataille F, Hagan S, Kolch W, Bosserhoff AK. Reduction in Raf kinase inhibitor protein expression is associated with increased Ras-extracellular signal-regulated kinase signaling in melanoma cell lines. Cancer Res. 2004;64:5186-92. (Pubitemid 39006537)
17. Hagan S, Al-Mulla F, Mallon E, Oien K, Ferrier R, Gusterson B, García JJ, Kolch W. Reduction of Raf-1 kinase inhibitor protein expression correlates with breast cancer metastasis. Clin Cancer Res. 2005;11:7392-7. (Pubitemid 41507699)
18. Li HZ, Gao Y, Zhao XL, Liu YX, Sun BC, Yang J, Yao Z. Effects of raf kinase inhibitor protein expression on metastasis and progression of human breast cancer. Mol Cancer Res. 2009;7:832-40.
19. Fu Z, Kitagawa Y, Shen R, Shah R, Mehra R, Rhodes D, Keller PJ, Mizokami A, Dunn R, Chinnaiyan AM, Yao Z, Keller ET. Metastasis suppressor gene Raf kinase inhibitor protein (RKIP) is a novel prognostic marker in prostate cancer. Prostate. 2006;66:248-56. (Pubitemid 43191224)
20. Houben R, Michel B, Vetter-Kauczok CS, Pfohler C, Laetsch B, Wolter MD, Leonard JH, Trefzer U, Ugurels, Schrama D, Becker JC. Absence of classical MAP kinase pathway signalling in Merkel cell carcinoma. J Invest Dermatol. 2006;126:1135-42.
21. Poulsen M. Merkel-cell carcinoma of the skin. Lancet Oncol. 2004;5:593-9. (Pubitemid 39303125)
22. Schuierer MM, Bataille F, Weiss TS, Hellerbrand C, Bosserhoff AK. Raf kinase inhibitor protein is downregulated in hepatocellular carcinoma. Oncol Rep. 2006;16:451-6.
23. Lee HC, Tian B, Sedivy JM, Wands JR, Kim M. Loss of Raf kinase inhibitor protein promotes cell proliferation and migration of human hepatoma cells. Gastroenterology. 2006;131:1208-17. (Pubitemid 44498689)
24. Al-Mulla F, Hagan S, Behbehani AI, Bitar MS, George SS, Going JJ, Garcia JJ, Scott L, Fyfe N, Murray GI, Kolch W. Raf kinase inhibitor protein expression in a survival analysis of colorectal cancer patients. J Clin Oncol. 2006;24:5672-9. (Pubitemid 46631308)
25. Zlobec I, Baker K, Terracciano L, Peter S, Degen L, Geglinger C, Lugli A. Two-marker protein profile predicts poor prognosis in patients with early rectal cancer. Br J Cancer. 2008;99:1712-7.
26. Akaishi J, Onda M, Asaka S, Okamoto J, Miyamoto S, Nagahama M, Ito K, Kawanami O, Shimizu K. Growth-suppressive function of phosphatidylethanolamine- binding protein in anaplastic thyroid cancer. Anticancer Res. 2006;26:4437-42. (Pubitemid 46031519)
27. Li HZ, Wang Y, Gao Y, Shao J, Zhao XL, Deng WM, Liu YX, Yang J, Yao Z. Effects of raf kinase inhibitor protein expression on metastasis and progression of human epithelial ovarian cancer. Mol Cancer Res. 2008;6: 917-28.
28. Chatterjee D, Sabo E, Tavares R, Resnick MB. Inverse association between Raf Kinase Inhibitory Protein and signal transducers and activators of transcription 3 expression in gastric adenocarcinoma patients: implications for clinical outcome. Clin Cancer Res. 2008;14: 2994-3001.
29. Martinho O, Gouveia A, Silva P, Pimenta A, Reis RM, Lopes JM. Loss of RKIP expression is associated with poor survival in GISTs. Virchows Arch. 2009;455:277-84.
30. Baritaki S, Huerta-Yepez S, Cabrava-Haimandez MD, Sensi M, Canevari S, Libra M, Penichet M, Chen H, Berenson JR, Bonavida B. Unique pattern of overexpression of Raf-1 kinase inhibitory protein (RKIP) in its inactivated phosphorylated form in human multiple myeloma. Immunopathological Dis Therapeut. 2010; forthcoming.